Dr. Kobos is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
# Memorial
New York, NY 10065Phone+1 212-639-5966
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2005 - 2008- New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 2002 - 2005
New York Medical CollegeClass of 2002
Certifications & Licensure
NY State Medical License 2004 - 2026- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Prospective Trial of Vaccine Responses in Childhood Cancer Survivors Start of enrollment: 2007 Jul 01
Publications & Presentations
PubMed
- 46 citationsPrognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA.Michele Cavo, Jesús F. San-Miguel, Saad Z. Usmani, Katja Weisel, Meletios A. Dimopoulos
Blood. 2021-07-21 - 56 citationsSustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE.Jesús F. San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, Shaji Kumar, Meletios A. Dimopoulos
Blood. 2021-07-16 - Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare.Nicole Gormley, Lola Fashoyin-Aje, Trevan Locke, Joseph M Unger, Richard F Little
Blood Cancer Discovery. 2021-03-01
Abstracts/Posters
- Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed ...Rachel Kobos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma...Rachel Kobos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Effectiveness of Daratumumab in Combination with Lenalidomide and Dexamethasone (DRd) Vs. Common Standard-of-Care Regimens in Patients with Non-Transplant Newly Diagno...Rachel Kobos, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
Lectures
- One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in P...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Clofarabine with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Children and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Janssen Presents Longer-Term Data for TECVAYLI® (Teclistamab-Cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple MyelomaJune 10th, 2023
- FDA Approves Biweekly Teclistamab Dosing Regimen for Patients with Multiple MyelomaFebruary 22nd, 2024
- FDA Approves Tecvayli at Reduced Dosing Frequency for Relapsed/Refractory Multiple MyelomaFebruary 24th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
